CoVaccine

CoVaccine B.V. was a Dutch biotechnology company specializing in the development of advanced vaccine adjuvants. The company's core technology, CoVaccine HT, is a proprietary adjuvant platform based on sucrose fatty acid sulfate esters designed to significantly boost the efficacy of vaccines by stimulating both B-cell and T-cell immune responses. CoVaccine HT has demonstrated a strong safety profile and potent immunostimulatory effects in various clinical and pre-clinical studies for indications such as influenza, malaria, and hepatitis. In 2010, the company was acquired by BTG plc (now part of Boston Scientific) for its strategic value in the vaccine and specialty pharmaceutical space. Today, the CoVaccine HT adjuvant continues to be utilized in various global health vaccine development programs through academic and commercial partnerships.